Cargando…
The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
Fistulizing Crohn’s disease (FCD) remains the most challenging aspect of treating patients with CD. FCD can occur in up to 30% of patients with CD and may lead to significant disability and impaired quality of life. The optimal treatment strategies for FCD require a multidisciplinary approach, inclu...
Autores principales: | Wetwittayakhlang, Panu, Al Khoury, Alex, Hahn, Gustavo Drügg, Lakatos, Peter Laszlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181669/ https://www.ncbi.nlm.nih.gov/pubmed/35683433 http://dx.doi.org/10.3390/jcm11113045 |
Ejemplares similares
-
Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022) -
Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022) -
Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023) -
Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021) -
The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)